Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
November 23, 2016
Juno Therapeutics (JUNO) JCAR015 P2 ROCKET trial on HOLD,
November 22, 2016
Fate Therapeutics (FATE), a $13.30 preferred combined with a $2.66 per share private placement for proceeds of $57 M
November 22, 2016
Biostage (BSTG) the “spin” is on; NASDAQ issued a continued listing deficiency notice
November 16, 2016
ImmunoCellular Therapeutics (NYSE MKT: IMUC) reverses itself out of a NYSEMKT listing issue
November 2, 2016
Opexa Therapeutics (OPXA) reduces workforce by 40%
November 1, 2016
Caladrius BioSciences (CLBS) partner, Sanford Research in P2 Type 1 Diabetes trial extends agreement
November 1, 2016
Organovo (ONVO) multiple customer orders for preclinical product … BUY
November 1, 2016
Pluristem Therapeutics (PSTI) P3 of Critical Limb Ischemia (CLI) cleared in UK
October 28, 2016
Opexa (OPXA) P2b Tcelna trial failed to meet endpoints
October 27, 2016
TiGenix NV (Euronext Brussels: TIG) proposes U.S. IPO
October 24, 2016
Histogenics (HSGX), ups enrollment numbers
October 24, 2016
Aduro Biotech (ADRO) reports Clinical Hold to pause enrollment in LADD trials
October 21, 2016
Northwest Biotherapeutics (NWBO) proposes 14 M share RDO at $0.38 to raise $5 M
October 20, 2016
Capricor Therapeutics (CAPR) NIH grant of $4.2 M to Evaluate Exosomes for Hypoplastic Left Heart Syndrome
October 19, 2016
Organovo Holdings (ONVO) proposes 9 M share offering at $2.75 per share to raise $25 M
October 6, 2016
AxoGen (AXGN) proposes offering of 2.33 M shares priced at $7.50
October 6, 2016
Mesoblast (ASX: MSB, MESO) P2 Trial Results in Diabetic Kidney Disease Published
September 27, 2016
bluebird bio (BLUE), European Medicines Agency (EMA) grants access to its Priority Medicines (PRIME)
September 16, 2016
Adverum Biotech (ADVM) pre-clinical data on 2 gene therapy candidates for the treatment of Wet AMD
September 16, 2016
Histogenics Corporation (HSGX) proposes $30 M Private Placement
September 15, 2016
Capricor Therapeutics (CAPR) proposes public offering of 3 M shares at $3.20
September 15, 2016
Caladrius Biosciences (CLBS) $25M two tranche At-market-offering without warrants - SELL
September 12, 2016
Vericel (VCEL) running out of cash, expands credit line - BUY
September 12, 2016
Neuralstem (CUR), $20 M private placement from Tianjin Pharmaceutical Holding Group - BUY
September 12, 2016
Athersys (ATHX) adjusts their feet on the starting block in the Japanese HELIOS clinical trial - BUY
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.